Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03831854 · ClinicalTrials.gov registry record · Phase 3
Lamotrigine in Reducing Psychologic Side-Effect of Perioperative Ketamine
A Phase 3 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
NCT03831854 is a Phase 3 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 46 participants.
The verdict
NCT03831854, a Phase 3 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
Study Summary
Patient will receive lamotrigine vs. placebo with small sips of water. Lamotrigine reaches peak level 1-4 hours after oral administration.
Interventions
- DRUG Placebo
- DRUG Ketamine
- DRUG Lamotrigine 300 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03831854
The ClinicalTrials.gov registry entry for NCT03831854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03831854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03831854 about?
NCT03831854 is a clinical study titled "Lamotrigine in Reducing Psychologic Side-Effect of Perioperative Ketamine". Patient will receive lamotrigine vs. placebo with small sips of water. Lamotrigine reaches peak level 1-4 hours after oral administration.
What is the current status of trial NCT03831854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2019-01-24. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03831854?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Lamotrigine 300 MG (DRUG).
Who is sponsoring clinical trial NCT03831854?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.